Research Profession Testifies Before Joint House & Senate Committee Hearing in Minnesota - Articles

Articles

Stay at the forefront of the consumer insights and analytics industry with our Thought Leadership content. Here you’ll find timely updates on the Insights Association’s advocacy efforts, including the latest legislative and regulatory developments that impact how we work. In addition, this section offers expert perspectives on innovative research techniques and methodologies, as well as valuable analysis of evolving consumer trends. Together, these insights provide a trusted resource for professionals looking to navigate change, elevate their practice, and shape the future of our industry.

Research Profession Testifies Before Joint House & Senate Committee Hearing in Minnesota

Research Profession Testifies Before Joint House & Senate Committee Hearing in Minnesota

(St. Paul, MN) The U.S. survey and research profession testified today before a joint hearing in the Minnesota House and Senate. The Marketing Research Association’s (MRA) Director of Government Affairs, Howard Fienberg, PLC, defended the use of physician incentives in pharmaceutical and medical device manufacturing.

“Thanks to a vaguely-crafted law and mis-guided interpretations, Minnesota is a dead zone for pharmaceutical marketing research with health care practitioners,” Howard testified. “The legislation being considered, H.F. 1641, would shift the regulatory authority and expand that dead zone to medical device research.”

The Minnesota House Commerce & Labor Committee and Senate Business, Jobs, & Industry Committee held a joint hearing January 25, 2010, on H.F. 1641 and two other pharmaceutical-related bills. Howard represented the research profession and its interests in testimony at the hearing, as part of his role as the industry’s U.S. lobbyist.

Pharmaceutical marketing research incentives have been prohibited in Minnesota. Even a change that would allow such payments to practitioners but require them to be publicly reported would not likely change the status quo for research. Pharmaceutical and medical device companies have stopped doing research in states with even the most rudimentary reporting requirements.

To date, the only exception has been Massachusetts, where MRA won an explicit exclusion for marketing research in regulations last year.

MRA also continues to lobby on the Physician Payments Sunshine Act at the federal level.

Related

Share

Login

Members only Article - Please login to view
  • Back to top